Patrick Forde: Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer
Patrick Forde, Professor at Johns Hopkins University, shared a post on X about a recent paper by him and colleagues published in Journal of Clinical Oncology:
“Now in Journal of Clinical Oncology led by Mark Awad and Mariano Provencio exploratory arm neoadjuvant ipi nivo for resectable lung cancer in CM816 with lots of interesting data! Combo neoadjuvant PD1-CTLA4 blockade without chemo likely not a viable strategy for all comers in NSCLC.”
“Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer”
Authors: Mark Awad, Patrick Forde, Nicolas Girard, Nan Hu, Mariano Provencio Pulla et al.
Dr. Patrick Forde is a Professor at Johns Hopkins University and Co-Director of the Division of Upper Aerodigestive Malignancies at the Sidney Kimmel Comprehensive Cancer Center. He also serves as the Director of the Thoracic Oncology Research Program at the Johns Hopkins University School of Medicine.
Dr. Forde’s research focuses on the role of immunotherapy in treating mesothelioma and lung cancer, and his work has led to the initiation of several ongoing phase 3 clinical trials.
More posts featuring Patrick Forde.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023